News headlines about Uroplasty (NASDAQ:UPI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Uroplasty earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the medical device company an impact score of 43.8904224405585 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s analysis:
- Uroplasty (UPI) vs. The Competition Financial Analysis (americanbankingnews.com)
- Analyzing Uroplasty (UPI) and Second Sight Medical Products (EYES) (americanbankingnews.com)
- Uroplasty (UPI) vs. The Competition Head-To-Head Survey (americanbankingnews.com)
- Uroplasty (UPI) versus Its Rivals Financial Analysis (americanbankingnews.com)
- Rescuers capture 17-foot cobra after three hour fight with python – UPI.com (upi.com)
Shares of Uroplasty (UPI) opened at $1.22 on Tuesday. Uroplasty has a 12-month low of $1.05 and a 12-month high of $4.05.
Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.
Receive News & Ratings for Uroplasty Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty Inc. and related companies with MarketBeat.com's FREE daily email newsletter.